BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology

Rhea-AI Summary

BD (NYSE: BDX) launched the CentroVena One™ Insertion System on April 29, 2026, the first all-in-one central venous catheter insertion device. The system consolidates introducer needle, syringe, guidewire and catheter to simplify workflow, received FDA 510(k) clearance, entered the FDA Safer Technologies Program, and is now commercially available in the U.S.

Positive

• Received FDA 510(k) clearance
• Accepted into the FDA Safer Technologies Program (STeP)
• Design claims: 30% fewer steps and 50% faster insertion time

Negative

• Time-reduction claim based on a simulation study (N = 49)
• Commercial availability currently limited to the U.S.

News Market Reaction – BDX

-2.82%

-2.82% Session close to close

In the Apr 29 session, BDX declined 2.82%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights BD’s commercial launch of the CentroVena One™ system, aiming to simplif...

Analysis

This announcement highlights BD’s commercial launch of the CentroVena One™ system, aiming to simplify central venous catheter placement and reduce complications. It builds on BD’s vascular access focus and follows recent clinical and regulatory milestones. Investors may track adoption trends, real‑world performance relative to the reported 30% workflow and 50% insertion‑time reductions, and how this new acute CVC offering complements BD’s broader vascular access portfolio and recent post‑spin financial profile with revenues of $18,544 million.

Key Figures

Revenue: $18,544 million Net income: $1,100 million Diluted EPS: $3.81 +5 more

8 metrics

Revenue $18,544 million Twelve months ended Sep 30, 2025 (continuing operations)

Net income $1,100 million Twelve months ended Sep 30, 2025 (continuing operations)

Diluted EPS $3.81 Twelve months ended Sep 30, 2025 (continuing operations)

Revenue prior year $16,820 million Twelve months ended Sep 30, 2024 (continuing operations)

Net income prior year $1,054 million Twelve months ended Sep 30, 2024 (continuing operations)

Diluted EPS prior year $3.62 Twelve months ended Sep 30, 2024 (continuing operations)

Workflow reduction 30% fewer steps CentroVena One™ vs traditional central venous catheter insertion

Insertion time reduction 50% reduction Head-to-head simulation study (N = 49) vs traditional CVC

Historical Context

5 past events · Latest: Apr 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Industry awards	Positive	-0.5%	Recognition for transparency, resiliency and partnership in healthcare supply chains.
Apr 09	Earnings date set	Neutral	-0.8%	Announcement of upcoming Q2 FY26 financial results and investor webcast details.
Apr 09	Executive retirement	Neutral	-0.8%	Planned retirement of Interventional segment leader after nearly 25 years at BD.
Apr 09	Clinical findings	Positive	-1.0%	Trial data showing PureWick® improved sleep and comfort for women with incontinence.
Apr 08	EU device approval	Positive	+1.4%	CE Marking for Liverty™ TIPS Stent Graft to treat portal hypertension in the EU.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news — including awards, clinical data and product approvals — often carried positive implications but did not consistently translate into positive next-day price moves, with several modest declines following favorable announcements.

Recent Company History

Over the past month, BD reported several developments: industry awards for supply chain resiliency on Apr 16, an upcoming Q2 FY26 earnings date on Apr 9, leadership retirement news, positive PureWick® clinical findings, and EU CE Marking for the Liverty™ TIPS Stent Graft on Apr 8. Despite generally constructive operational updates, next‑day price reactions were mixed, with some positive medical and recognition news coinciding with small declines. Today’s U.S. launch of the CentroVena One™ system continues BD’s focus on vascular access innovation.

Key Terms

central venous catheter, pneumothorax, air embolism, guidewire embolism, +4 more

8 terms

central venous catheter medical

"the first all-in-one central venous catheter (CVC) insertion device on the market"

A central venous catheter is a thin, flexible tube placed into a large vein near the neck, chest, or groin to deliver medications, fluids, nutrition, or to measure pressures inside the body. For investors it matters because demand, safety, infection risk, and regulatory changes around these devices and the procedures to place them can affect hospital spending, device makers’ sales, and liability or reimbursement trends—think of it as a dedicated shipping lane for critical medical treatments.

pneumothorax medical

"increase the risk of complications such as pneumothorax, arterial injury, air or guidewire"

Air collecting between the lung and chest wall causing part or all of a lung to collapse; imagine a balloon inside a box that loses air and shrinks, reducing breathing capacity and often requiring urgent medical care. For investors, pneumothorax matters because it can drive hospital stays, treatment demand, liability or trial stoppages, and costs for companies in healthcare, insurance, and medical-device sectors.

air embolism medical

"increase the risk of complications such as pneumothorax, arterial injury, air or guidewire embolism"

An air embolism is a dangerous medical event where one or more air bubbles enter the bloodstream and block blood flow to organs, like a small balloon clogging a pipe. For investors, it matters because such events can trigger safety investigations, regulatory action, product recalls or liability claims for healthcare companies, potentially affecting clinical trial outcomes, sales, reputation and a company’s stock value.

guidewire embolism medical

"clip permanently attached to the guidewire, designed to prevent guidewire embolism"

A guidewire embolism is a rare medical complication in which a thin wire used to guide catheters during procedures breaks or slips and travels through blood vessels, potentially lodging in the heart, lungs, or other organs. For investors, it matters because such events can trigger patient harm, device recalls, regulatory investigations or legal claims, which can affect a medical device maker’s sales, reputation and future regulatory approvals — much like a lodged splinter disrupting an otherwise smooth pipeline.

needlestick injury medical

"needle with integrated passive needle safety, designed to reduce the risk of needlestick injury"

A needlestick injury occurs when a used needle or other sharp medical device accidentally punctures a person’s skin, potentially exposing them to bloodborne infections or hazardous drugs. Investors should care because such injuries create direct medical and legal costs, can trigger regulatory scrutiny and workplace-safety investigations, and may damage reputation and operational continuity in healthcare or manufacturing settings—similar to a workplace accident that can halt production and raise liability expenses.

bloodstream infections medical

"increase the risk of complications such as ... air or guidewire embolism, bloodstream infections"

Bloodstream infections occur when bacteria, fungi, or other microbes enter and multiply in the blood, allowing the infection to spread quickly throughout the body—similar to contaminants circulating in a city’s water system. Investors care because these infections drive demand for diagnostics, antibiotics, sterile devices and infection-control services, influence hospital costs and patient outcomes, and can materially affect the sales, regulatory review and valuation of healthcare companies involved in treatment and prevention.

510(k) clearance regulatory

"The CentroVena One™ Insertion System received U.S. FDA 510(k) clearance and was accepted"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

safer technologies program regulatory

"accepted into the FDA Safer Technologies Program (STeP) for Medical Devices"

A safer technologies program is an initiative—often run by regulators or companies—to identify, promote or require products and processes that reduce harm to people, property or the environment. For investors it signals shifting rules, costs and market demand: companies that adopt approved safer options may avoid fines and gain sales, while those slow to adapt can face extra expenses or lost market access, much like choosing to meet new safety standards early.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

With the launch of CentroVena One™, BD brings a first‑of‑its‑kind insertion system to market that simplifies central line placement for clinicians and enhances care in acute settings

FRANKLIN LAKES, N.J., April 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the BD® CentroVena One™ Insertion System, the first all-in-one central venous catheter (CVC) insertion device on the market. The system is designed to simplify central line placement for clinicians and enhance patient safety by streamlining key steps and incorporating safety-focused design elements that support consistent, efficient care in high-pressure acute settings.

"CentroVena One™ represents the most meaningful advancement in central line insertion since the technique was first introduced nearly seven decades ago," said Ron Silverman, executive vice president and chief medical officer at BD. "By reducing procedural steps, helping protect against preventable complications and simplifying one of the most stressful procedures clinicians perform, we're supporting safer, faster care for patients when every second counts."

Central line insertion is performed millions of times each year in the U.S., yet the traditional process remains complex. It requires multiple component exchanges that can introduce contamination, create workflow delays and increase the risk of complications such as pneumothorax, arterial injury, air or guidewire embolism, bloodstream infections and needlestick injuries.

The CentroVena One™ Insertion System helps address these challenges by consolidating essential components – including the introducer needle, syringe, guidewire and catheter – into a single platform. Compared to the current standard of care, this innovative approach is designed to:

• Simplify workflow with 30% fewer steps
• Reduce insertion time by 50%^*
• Reduce contamination risk by minimizing touchpoints during catheter insertion
• Help protect against insertion-related complications

UNC Health Blue Ridge is among the first health systems to pilot the CentroVena One™ system in patient care as part of an initial clinical evaluation. 

"Central line placement is one of the highest-pressure bedside procedures our teams perform – especially in fast-moving, high-acuity environments where unpredictability is inherent and skilled clinicians must bring precision to complexity in real time," said Anthony Frank, MD, MBA, FACEP, chief medical officer and senior vice president of Medical Affairs at UNC Health Blue Ridge. "What stands out in our early experience with CentroVena One™ is its intentional design around real-world clinical challenges – streamlining catheter placement while reducing opportunities for error, sterile field breaches and overall workload. Innovations that better support frontline teams in this way align directly with our commitment to patient safety, high-quality care and infection prevention."

Key features of the CentroVena One™ Insertion System include:

• Pre-loaded kink-resistant guidewire
• Integrated drape clip permanently attached to the guidewire, designed to prevent guidewire embolism
• Pre-loaded catheter with self-dilating tip, eliminating the need for a separate dilation step
• Introducer needle with integrated passive needle safety, designed to reduce the risk of needlestick injury
• Closed insertion system designed to help reduce the risk of air embolism, clinician blood exposure and patient blood loss

The CentroVena One™ Insertion System received U.S. FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program (STeP) for Medical Devices, a prestigious recognition for substantial safety innovations.

The commercial launch of CentroVena One™ marks BD's entry into the acute CVC market and expands its vascular access portfolio. As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy by helping reduce the risk of vascular access-related complications, improving clinical and economic outcomes and increasing patient satisfaction, supporting health care facilities in moving closer to a vision of a "one-stick patient experience."

CentroVena One™ is now commercially available in the U.S. For more information, visit bd.com/CentroVenaOne.

^*Compared to a traditional CVC in a head-to-head simulation study (N = 49) published in The Journal of Emergency Medicine (December 2025). Results may not reflect actual clinical performance.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-reimagines-central-line-insertion-advancing-leadership-in-patient-safety-through-breakthrough-vascular-access-technology-302757091.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What is the CentroVena One™ system announced by BD (BDX) on April 29, 2026?

CentroVena One™ is an all-in-one central venous catheter insertion system designed to consolidate components for central line placement. According to BD, it integrates needle, syringe, guidewire and catheter to streamline steps and enhance safety in acute care settings.

Does CentroVena One™ have FDA clearance and regulatory recognition for safety?

Yes. CentroVena One™ received U.S. FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program. According to BD, both milestones recognize the device's safety-focused design innovations.

What performance improvements does BD claim for CentroVena One™ compared with traditional CVCs?

BD claims CentroVena One™ reduces procedural steps by 30% and insertion time by 50% in simulation. According to BD, the 50% insertion-time result comes from a head-to-head simulation study (N = 49) published in December 2025.

Is CentroVena One™ commercially available and where can clinicians obtain it?

CentroVena One™ is now commercially available in the United States. According to BD, clinicians and health systems can find more information and ordering details through BD's commercial channels and the company website.

How strong is the clinical evidence supporting CentroVena One™'s claimed benefits?

Early evidence includes a published simulation study (N = 49) and initial pilot use at UNC Health Blue Ridge. According to BD, results may not reflect actual clinical performance outside simulation and early evaluations.